Document Detail

Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight?
MedLine Citation:
PMID:  10207553     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Prophylactic zidovudine during pregnancy and labour reduces maternal viral load and, with neonatal therapy, has been shown to reduce vertical transmission. However, zidovudine may have additional effects. Advanced HIV disease is associated with premature delivery, which in turn results in increased vertical transmission. Data from the European Collaborative Study (ECS) were analysed to investigate whether zidovudine could be associated with decreased prematurity risk and/or with a reduced frequency of low birthweight.
METHODS: HIV-infected pregnant women enrolled in the ECS were followed prospectively according to a standard protocol. Gestational age was assessed by ultrasound, prematurity was defined as delivery before 37 weeks and the cut-off for low birthweight was 2500 g. We calculated odds ratios (OR) to estimate the effect of zidovudine on the risk of premature of low birthweight delivery.
RESULTS: In 2299 mothers, zidovudine taken to reduce the risk of vertical transmission decreased the odds of premature delivery by a quarter (OR = 0.76, 95% confidence interval (CI) 0.53-1.09), and the odds of low birthweight by nearly half (OR = 0.55, 95% CI 0.39-0.79). Allowing for CD4 count and mode of delivery did not greatly alter these OR values. A multivariate analysis suggested that prophylactic zidovudine and prematurity were independently associated with risk of transmission.
CONCLUSION: Our findings suggest an additional health benefit of zidovudine. Even if most vertical transmission occurs around the time of delivery, therapy earlier in pregnancy could have an indirect effect on transmission rates through delaying delivery. This hypothesis needs to be confirmed or refuted by more appropriate studies.
Related Documents :
10599993 - Plasminogen activator inhibitor activity: an independent risk factor for the high misca...
9699743 - High third-trimester ferritin concentration: associations with very preterm delivery, i...
22432143 - Placental corticotrophin-releasing hormone, local effects and fetomaternal endocrinology.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  AIDS (London, England)     Volume:  13     ISSN:  0269-9370     ISO Abbreviation:  AIDS     Publication Date:  1999 Jan 
Date Detail:
Created Date:  1999-06-28     Completed Date:  1999-06-28     Revised Date:  2013-09-24    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  119-24     Citation Subset:  IM; X    
Department of Epidemology and Public Health, Institute of Child Health, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-HIV Agents / therapeutic use*
Birth Weight
CD4 Lymphocyte Count
Gestational Age
HIV Infections / drug therapy*,  immunology,  transmission
Infant, Newborn
Pregnancy Complications, Infectious / drug therapy*,  immunology
Reverse Transcriptase Inhibitors / therapeutic use*
Zidovudine / therapeutic use*
Reg. No./Substance:
0/Anti-HIV Agents; 0/Reverse Transcriptase Inhibitors; 30516-87-1/Zidovudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Côte d'Ivoire.
Next Document:  Post-partum sexual abstinence in West Africa: implications for AIDS-control and family planning prog...